Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Proteogenomics provides molecular insights into endometrial carcinoma

Publish date:: February 19, 2020

Key clinical point: A systematic proteogenomic analysis has revealed novel insights into the underlying molecular and immune mechanisms of endometrial carcinoma.

Major finding: The measurement of tumor antigen presentation defects could be more effective than measuring tumor mutation burden in the selection of immunotherapy for patients with endometrial carcinoma.

Study details: A multiomic analysis of 95 endometrial carcinoma tumor samples.

Disclosures: The study was funded by the National Cancer Institute, the Cancer Prevention & Research Institutes of Texas, and the Robert and Janice McNair Foundation. The authors reported having no conflicts of interest.

Citation:

Dou Y et al. Cell. 2020 Feb 13. doi: 10.1016/j.cell.2020.01.026.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gynecologic Cancer

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

Is diagnostic hysteroscopy safe in patients with type 2 endometrial cancer?,

Cervical cancer recurrence patterns differ after laparoscopic and open hysterectomy,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Half of women treated for gynecologic cancers miss or skip doses of oral drugs,